| Old | New | Differences | |
|---|---|---|---|
| 1 | - | Public Act 103-0245 | |
| 2 | 1 | SB1987 EnrolledLRB103 25792 RLC 57149 b SB1987 Enrolled LRB103 25792 RLC 57149 b | |
| 3 | 2 | SB1987 Enrolled LRB103 25792 RLC 57149 b | |
| 4 | - | AN ACT concerning criminal law. | |
| 5 | - | Be it enacted by the People of the State of Illinois, | |
| 6 | - | represented in the General Assembly: | |
| 7 | - | Section 5. The Illinois Controlled Substances Act is | |
| 8 | - | amended by changing Section 204 as follows: | |
| 9 | - | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | |
| 10 | - | Sec. 204. (a) The controlled substances listed in this | |
| 11 | - | Section are included in Schedule I. | |
| 12 | - | (b) Unless specifically excepted or unless listed in | |
| 13 | - | another schedule, any of the following opiates, including | |
| 14 | - | their isomers, esters, ethers, salts, and salts of isomers, | |
| 15 | - | esters, and ethers, whenever the existence of such isomers, | |
| 16 | - | esters, ethers and salts is possible within the specific | |
| 17 | - | chemical designation: | |
| 18 | - | (1) Acetylmethadol; | |
| 19 | - | (1.1) Acetyl-alpha-methylfentanyl | |
| 20 | - | (N-[1-(1-methyl-2-phenethyl)- | |
| 21 | - | 4-piperidinyl]-N-phenylacetamide); | |
| 22 | - | (2) Allylprodine; | |
| 23 | - | (3) Alphacetylmethadol, except | |
| 24 | - | levo-alphacetylmethadol (also known as levo-alpha- | |
| 25 | - | acetylmethadol, levomethadyl acetate, or LAAM); | |
| 26 | - | (4) Alphameprodine; | |
| 3 | + | 1 AN ACT concerning criminal law. | |
| 4 | + | 2 Be it enacted by the People of the State of Illinois, | |
| 5 | + | 3 represented in the General Assembly: | |
| 6 | + | 4 Section 5. The Illinois Controlled Substances Act is | |
| 7 | + | 5 amended by changing Section 204 as follows: | |
| 8 | + | 6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | |
| 9 | + | 7 Sec. 204. (a) The controlled substances listed in this | |
| 10 | + | 8 Section are included in Schedule I. | |
| 11 | + | 9 (b) Unless specifically excepted or unless listed in | |
| 12 | + | 10 another schedule, any of the following opiates, including | |
| 13 | + | 11 their isomers, esters, ethers, salts, and salts of isomers, | |
| 14 | + | 12 esters, and ethers, whenever the existence of such isomers, | |
| 15 | + | 13 esters, ethers and salts is possible within the specific | |
| 16 | + | 14 chemical designation: | |
| 17 | + | 15 (1) Acetylmethadol; | |
| 18 | + | 16 (1.1) Acetyl-alpha-methylfentanyl | |
| 19 | + | 17 (N-[1-(1-methyl-2-phenethyl)- | |
| 20 | + | 18 4-piperidinyl]-N-phenylacetamide); | |
| 21 | + | 19 (2) Allylprodine; | |
| 22 | + | 20 (3) Alphacetylmethadol, except | |
| 23 | + | 21 levo-alphacetylmethadol (also known as levo-alpha- | |
| 24 | + | 22 acetylmethadol, levomethadyl acetate, or LAAM); | |
| 25 | + | 23 (4) Alphameprodine; | |
| 27 | 26 | ||
| 28 | 27 | ||
| 29 | 28 | ||
| 30 | 29 | SB1987 Enrolled LRB103 25792 RLC 57149 b | |
| 31 | 30 | ||
| 32 | 31 | ||
| 33 | - | (5) Alphamethadol; | |
| 34 | - | (6) Alpha-methylfentanyl | |
| 35 | - | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl) | |
| 36 | - | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N- | |
| 37 | - | propanilido) piperidine; | |
| 38 | - | (6.1) Alpha-methylthiofentanyl | |
| 39 | - | (N-[1-methyl-2-(2-thienyl)ethyl- | |
| 40 | - | 4-piperidinyl]-N-phenylpropanamide); | |
| 41 | - | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | |
| 42 | - | (7.1) PEPAP | |
| 43 | - | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | |
| 44 | - | (8) Benzethidine; | |
| 45 | - | (9) Betacetylmethadol; | |
| 46 | - | (9.1) Beta-hydroxyfentanyl | |
| 47 | - | (N-[1-(2-hydroxy-2-phenethyl)- | |
| 48 | - | 4-piperidinyl]-N-phenylpropanamide); | |
| 49 | - | (10) Betameprodine; | |
| 50 | - | (11) Betamethadol; | |
| 51 | - | (12) Betaprodine; | |
| 52 | - | (13) Clonitazene; | |
| 53 | - | (14) Dextromoramide; | |
| 54 | - | (15) Diampromide; | |
| 55 | - | (16) Diethylthiambutene; | |
| 56 | - | (17) Difenoxin; | |
| 57 | - | (18) Dimenoxadol; | |
| 58 | - | (19) Dimepheptanol; | |
| 32 | + | SB1987 Enrolled- 2 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 2 - LRB103 25792 RLC 57149 b | |
| 33 | + | SB1987 Enrolled - 2 - LRB103 25792 RLC 57149 b | |
| 34 | + | 1 (5) Alphamethadol; | |
| 35 | + | 2 (6) Alpha-methylfentanyl | |
| 36 | + | 3 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl) | |
| 37 | + | 4 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N- | |
| 38 | + | 5 propanilido) piperidine; | |
| 39 | + | 6 (6.1) Alpha-methylthiofentanyl | |
| 40 | + | 7 (N-[1-methyl-2-(2-thienyl)ethyl- | |
| 41 | + | 8 4-piperidinyl]-N-phenylpropanamide); | |
| 42 | + | 9 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | |
| 43 | + | 10 (7.1) PEPAP | |
| 44 | + | 11 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | |
| 45 | + | 12 (8) Benzethidine; | |
| 46 | + | 13 (9) Betacetylmethadol; | |
| 47 | + | 14 (9.1) Beta-hydroxyfentanyl | |
| 48 | + | 15 (N-[1-(2-hydroxy-2-phenethyl)- | |
| 49 | + | 16 4-piperidinyl]-N-phenylpropanamide); | |
| 50 | + | 17 (10) Betameprodine; | |
| 51 | + | 18 (11) Betamethadol; | |
| 52 | + | 19 (12) Betaprodine; | |
| 53 | + | 20 (13) Clonitazene; | |
| 54 | + | 21 (14) Dextromoramide; | |
| 55 | + | 22 (15) Diampromide; | |
| 56 | + | 23 (16) Diethylthiambutene; | |
| 57 | + | 24 (17) Difenoxin; | |
| 58 | + | 25 (18) Dimenoxadol; | |
| 59 | + | 26 (19) Dimepheptanol; | |
| 59 | 60 | ||
| 60 | 61 | ||
| 61 | - | (20) Dimethylthiambutene; | |
| 62 | - | (21) Dioxaphetylbutyrate; | |
| 63 | - | (22) Dipipanone; | |
| 64 | - | (23) Ethylmethylthiambutene; | |
| 65 | - | (24) Etonitazene; | |
| 66 | - | (25) Etoxeridine; | |
| 67 | - | (26) Furethidine; | |
| 68 | - | (27) Hydroxpethidine; | |
| 69 | - | (28) Ketobemidone; | |
| 70 | - | (29) Levomoramide; | |
| 71 | - | (30) Levophenacylmorphan; | |
| 72 | - | (31) 3-Methylfentanyl | |
| 73 | - | (N-[3-methyl-1-(2-phenylethyl)- | |
| 74 | - | 4-piperidyl]-N-phenylpropanamide); | |
| 75 | - | (31.1) 3-Methylthiofentanyl | |
| 76 | - | (N-[(3-methyl-1-(2-thienyl)ethyl- | |
| 77 | - | 4-piperidinyl]-N-phenylpropanamide); | |
| 78 | - | (32) Morpheridine; | |
| 79 | - | (33) Noracymethadol; | |
| 80 | - | (34) Norlevorphanol; | |
| 81 | - | (35) Normethadone; | |
| 82 | - | (36) Norpipanone; | |
| 83 | - | (36.1) Para-fluorofentanyl | |
| 84 | - | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)- | |
| 85 | - | 4-piperidinyl]propanamide); | |
| 86 | - | (37) Phenadoxone; | |
| 87 | 62 | ||
| 88 | 63 | ||
| 89 | - | (38) Phenampromide; | |
| 90 | - | (39) Phenomorphan; | |
| 91 | - | (40) Phenoperidine; | |
| 92 | - | (41) Piritramide; | |
| 93 | - | (42) Proheptazine; | |
| 94 | - | (43) Properidine; | |
| 95 | - | (44) Propiram; | |
| 96 | - | (45) Racemoramide; | |
| 97 | - | (45.1) Thiofentanyl | |
| 98 | - | (N-phenyl-N-[1-(2-thienyl)ethyl- | |
| 99 | - | 4-piperidinyl]-propanamide); | |
| 100 | - | (46) Tilidine; | |
| 101 | - | (47) Trimeperidine; | |
| 102 | - | (48) Beta-hydroxy-3-methylfentanyl (other name: | |
| 103 | - | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]- | |
| 104 | - | N-phenylpropanamide); | |
| 105 | - | (49) Furanyl fentanyl (FU-F); | |
| 106 | - | (50) Butyryl fentanyl; | |
| 107 | - | (51) Valeryl fentanyl; | |
| 108 | - | (52) Acetyl fentanyl; | |
| 109 | - | (53) Beta-hydroxy-thiofentanyl; | |
| 110 | - | (54) 3,4-dichloro-N-[2- | |
| 111 | - | (dimethylamino)cyclohexyl]-N- | |
| 112 | - | methylbenzamide (U-47700); | |
| 113 | - | (55) 4-chloro-N-[1-[2- | |
| 114 | - | (4-nitrophenyl)ethyl]-2-piperidinylidene]- | |
| 64 | + | ||
| 65 | + | SB1987 Enrolled - 2 - LRB103 25792 RLC 57149 b | |
| 115 | 66 | ||
| 116 | 67 | ||
| 117 | - | benzenesulfonamide (W-18); | |
| 118 | - | (56) 4-chloro-N-[1-(2-phenylethyl) | |
| 119 | - | -2-piperidinylidene]-benzenesulfonamide (W-15); | |
| 120 | - | (57) acrylfentanyl (acryloylfentanyl). | |
| 121 | - | (c) Unless specifically excepted or unless listed in | |
| 122 | - | another schedule, any of the following opium derivatives, its | |
| 123 | - | salts, isomers and salts of isomers, whenever the existence of | |
| 124 | - | such salts, isomers and salts of isomers is possible within | |
| 125 | - | the specific chemical designation: | |
| 126 | - | (1) Acetorphine; | |
| 127 | - | (2) Acetyldihydrocodeine; | |
| 128 | - | (3) Benzylmorphine; | |
| 129 | - | (4) Codeine methylbromide; | |
| 130 | - | (5) Codeine-N-Oxide; | |
| 131 | - | (6) Cyprenorphine; | |
| 132 | - | (7) Desomorphine; | |
| 133 | - | (8) Diacetyldihydromorphine (Dihydroheroin); | |
| 134 | - | (9) Dihydromorphine; | |
| 135 | - | (10) Drotebanol; | |
| 136 | - | (11) Etorphine (except hydrochloride salt); | |
| 137 | - | (12) Heroin; | |
| 138 | - | (13) Hydromorphinol; | |
| 139 | - | (14) Methyldesorphine; | |
| 140 | - | (15) Methyldihydromorphine; | |
| 141 | - | (16) Morphine methylbromide; | |
| 142 | - | (17) Morphine methylsulfonate; | |
| 68 | + | SB1987 Enrolled- 3 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 3 - LRB103 25792 RLC 57149 b | |
| 69 | + | SB1987 Enrolled - 3 - LRB103 25792 RLC 57149 b | |
| 70 | + | 1 (20) Dimethylthiambutene; | |
| 71 | + | 2 (21) Dioxaphetylbutyrate; | |
| 72 | + | 3 (22) Dipipanone; | |
| 73 | + | 4 (23) Ethylmethylthiambutene; | |
| 74 | + | 5 (24) Etonitazene; | |
| 75 | + | 6 (25) Etoxeridine; | |
| 76 | + | 7 (26) Furethidine; | |
| 77 | + | 8 (27) Hydroxpethidine; | |
| 78 | + | 9 (28) Ketobemidone; | |
| 79 | + | 10 (29) Levomoramide; | |
| 80 | + | 11 (30) Levophenacylmorphan; | |
| 81 | + | 12 (31) 3-Methylfentanyl | |
| 82 | + | 13 (N-[3-methyl-1-(2-phenylethyl)- | |
| 83 | + | 14 4-piperidyl]-N-phenylpropanamide); | |
| 84 | + | 15 (31.1) 3-Methylthiofentanyl | |
| 85 | + | 16 (N-[(3-methyl-1-(2-thienyl)ethyl- | |
| 86 | + | 17 4-piperidinyl]-N-phenylpropanamide); | |
| 87 | + | 18 (32) Morpheridine; | |
| 88 | + | 19 (33) Noracymethadol; | |
| 89 | + | 20 (34) Norlevorphanol; | |
| 90 | + | 21 (35) Normethadone; | |
| 91 | + | 22 (36) Norpipanone; | |
| 92 | + | 23 (36.1) Para-fluorofentanyl | |
| 93 | + | 24 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)- | |
| 94 | + | 25 4-piperidinyl]propanamide); | |
| 95 | + | 26 (37) Phenadoxone; | |
| 143 | 96 | ||
| 144 | 97 | ||
| 145 | - | (18) Morphine-N-Oxide; | |
| 146 | - | (19) Myrophine; | |
| 147 | - | (20) Nicocodeine; | |
| 148 | - | (21) Nicomorphine; | |
| 149 | - | (22) Normorphine; | |
| 150 | - | (23) Pholcodine; | |
| 151 | - | (24) Thebacon. | |
| 152 | - | (d) Unless specifically excepted or unless listed in | |
| 153 | - | another schedule, any material, compound, mixture, or | |
| 154 | - | preparation which contains any quantity of the following | |
| 155 | - | hallucinogenic substances, or which contains any of its salts, | |
| 156 | - | isomers and salts of isomers, whenever the existence of such | |
| 157 | - | salts, isomers, and salts of isomers is possible within the | |
| 158 | - | specific chemical designation (for the purposes of this | |
| 159 | - | paragraph only, the term "isomer" includes the optical, | |
| 160 | - | position and geometric isomers): | |
| 161 | - | (1) 3,4-methylenedioxyamphetamine | |
| 162 | - | (alpha-methyl,3,4-methylenedioxyphenethylamine, | |
| 163 | - | methylenedioxyamphetamine, MDA); | |
| 164 | - | (1.1) Alpha-ethyltryptamine | |
| 165 | - | (some trade or other names: etryptamine; | |
| 166 | - | MONASE; alpha-ethyl-1H-indole-3-ethanamine; | |
| 167 | - | 3-(2-aminobutyl)indole; a-ET; and AET); | |
| 168 | - | (2) 3,4-methylenedioxymethamphetamine (MDMA); | |
| 169 | - | (2.1) 3,4-methylenedioxy-N-ethylamphetamine | |
| 170 | - | (also known as: N-ethyl-alpha-methyl- | |
| 171 | 98 | ||
| 172 | 99 | ||
| 173 | - | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE, | |
| 174 | - | and MDEA); | |
| 175 | - | (2.2) N-Benzylpiperazine (BZP); | |
| 176 | - | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | |
| 177 | - | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | |
| 178 | - | (4) 3,4,5-trimethoxyamphetamine (TMA); | |
| 179 | - | (5) (Blank); | |
| 180 | - | (6) Diethyltryptamine (DET); | |
| 181 | - | (7) Dimethyltryptamine (DMT); | |
| 182 | - | (7.1) 5-Methoxy-diallyltryptamine; | |
| 183 | - | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | |
| 184 | - | (9) Ibogaine (some trade and other names: | |
| 185 | - | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy- | |
| 186 | - | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b] | |
| 187 | - | indole; Tabernanthe iboga); | |
| 188 | - | (10) Lysergic acid diethylamide; | |
| 189 | - | (10.1) Salvinorin A; | |
| 190 | - | (10.5) Salvia divinorum (meaning all parts of the | |
| 191 | - | plant presently classified botanically as Salvia | |
| 192 | - | divinorum, whether growing or not, the seeds thereof, any | |
| 193 | - | extract from any part of that plant, and every compound, | |
| 194 | - | manufacture, salts, isomers, and salts of isomers whenever | |
| 195 | - | the existence of such salts, isomers, and salts of isomers | |
| 196 | - | is possible within the specific chemical designation, | |
| 197 | - | derivative, mixture, or preparation of that plant, its | |
| 198 | - | seeds or extracts); | |
| 100 | + | ||
| 101 | + | SB1987 Enrolled - 3 - LRB103 25792 RLC 57149 b | |
| 199 | 102 | ||
| 200 | 103 | ||
| 201 | - | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | |
| 202 | - | (12) Peyote (meaning all parts of the plant presently | |
| 203 | - | classified botanically as Lophophora williamsii Lemaire, | |
| 204 | - | whether growing or not, the seeds thereof, any extract | |
| 205 | - | from any part of that plant, and every compound, | |
| 206 | - | manufacture, salts, derivative, mixture, or preparation of | |
| 207 | - | that plant, its seeds or extracts); | |
| 208 | - | (13) N-ethyl-3-piperidyl benzilate (JB 318); | |
| 209 | - | (14) N-methyl-3-piperidyl benzilate; | |
| 210 | - | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine | |
| 211 | - | (also known as N-hydroxy-alpha-methyl- | |
| 212 | - | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | |
| 213 | - | (15) Parahexyl; some trade or other names: | |
| 214 | - | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- | |
| 215 | - | dibenzo (b,d) pyran; Synhexyl; | |
| 216 | - | (16) Psilocybin; | |
| 217 | - | (17) Psilocyn; | |
| 218 | - | (18) Alpha-methyltryptamine (AMT); | |
| 219 | - | (19) 2,5-dimethoxyamphetamine | |
| 220 | - | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | |
| 221 | - | (20) 4-bromo-2,5-dimethoxyamphetamine | |
| 222 | - | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; | |
| 223 | - | 4-bromo-2,5-DMA); | |
| 224 | - | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine. | |
| 225 | - | Some trade or other names: 2-(4-bromo- | |
| 226 | - | 2,5-dimethoxyphenyl)-1-aminoethane; | |
| 104 | + | SB1987 Enrolled- 4 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 4 - LRB103 25792 RLC 57149 b | |
| 105 | + | SB1987 Enrolled - 4 - LRB103 25792 RLC 57149 b | |
| 106 | + | 1 (38) Phenampromide; | |
| 107 | + | 2 (39) Phenomorphan; | |
| 108 | + | 3 (40) Phenoperidine; | |
| 109 | + | 4 (41) Piritramide; | |
| 110 | + | 5 (42) Proheptazine; | |
| 111 | + | 6 (43) Properidine; | |
| 112 | + | 7 (44) Propiram; | |
| 113 | + | 8 (45) Racemoramide; | |
| 114 | + | 9 (45.1) Thiofentanyl | |
| 115 | + | 10 (N-phenyl-N-[1-(2-thienyl)ethyl- | |
| 116 | + | 11 4-piperidinyl]-propanamide); | |
| 117 | + | 12 (46) Tilidine; | |
| 118 | + | 13 (47) Trimeperidine; | |
| 119 | + | 14 (48) Beta-hydroxy-3-methylfentanyl (other name: | |
| 120 | + | 15 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]- | |
| 121 | + | 16 N-phenylpropanamide); | |
| 122 | + | 17 (49) Furanyl fentanyl (FU-F); | |
| 123 | + | 18 (50) Butyryl fentanyl; | |
| 124 | + | 19 (51) Valeryl fentanyl; | |
| 125 | + | 20 (52) Acetyl fentanyl; | |
| 126 | + | 21 (53) Beta-hydroxy-thiofentanyl; | |
| 127 | + | 22 (54) 3,4-dichloro-N-[2- | |
| 128 | + | 23 (dimethylamino)cyclohexyl]-N- | |
| 129 | + | 24 methylbenzamide (U-47700); | |
| 130 | + | 25 (55) 4-chloro-N-[1-[2- | |
| 131 | + | 26 (4-nitrophenyl)ethyl]-2-piperidinylidene]- | |
| 227 | 132 | ||
| 228 | 133 | ||
| 229 | - | alpha-desmethyl DOB, 2CB, Nexus; | |
| 230 | - | (21) 4-methoxyamphetamine | |
| 231 | - | (4-methoxy-alpha-methylphenethylamine; | |
| 232 | - | paramethoxyamphetamine; PMA); | |
| 233 | - | (22) (Blank); | |
| 234 | - | (23) Ethylamine analog of phencyclidine. | |
| 235 | - | Some trade or other names: | |
| 236 | - | N-ethyl-1-phenylcyclohexylamine, | |
| 237 | - | (1-phenylcyclohexyl) ethylamine, | |
| 238 | - | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | |
| 239 | - | (24) Pyrrolidine analog of phencyclidine. Some trade | |
| 240 | - | or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | |
| 241 | - | PHP; | |
| 242 | - | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | |
| 243 | - | (26) 2,5-dimethoxy-4-ethylamphetamine | |
| 244 | - | (another name: DOET); | |
| 245 | - | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine | |
| 246 | - | (another name: TCPy); | |
| 247 | - | (28) (Blank); | |
| 248 | - | (29) Thiophene analog of phencyclidine (some trade | |
| 249 | - | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; | |
| 250 | - | 2-thienyl analog of phencyclidine; TPCP; TCP); | |
| 251 | - | (29.1) Benzothiophene analog of phencyclidine. Some | |
| 252 | - | trade or other names: BTCP or benocyclidine; | |
| 253 | - | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); | |
| 254 | - | (30) Bufotenine (some trade or other names: | |
| 255 | 134 | ||
| 256 | 135 | ||
| 257 | - | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole; | |
| 258 | - | 3-(2-dimethylaminoethyl)-5-indolol; | |
| 259 | - | 5-hydroxy-N,N-dimethyltryptamine; | |
| 260 | - | N,N-dimethylserotonin; mappine); | |
| 261 | - | (31) (Blank); | |
| 262 | - | (32) (Blank); | |
| 263 | - | (33) (Blank); | |
| 264 | - | (34) (Blank); | |
| 265 | - | (34.5) (Blank); | |
| 266 | - | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | |
| 267 | - | (2-methyloctan-2-yl)-6a,7, | |
| 268 | - | 10,10a-tetrahydrobenzo[c]chromen-1-ol | |
| 269 | - | Some trade or other names: HU-210; | |
| 270 | - | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | |
| 271 | - | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | |
| 272 | - | tetrahydrobenzo[c]chromen-1-ol, its isomers, | |
| 273 | - | salts, and salts of isomers; Some trade or other | |
| 274 | - | names: HU-210, Dexanabinol; | |
| 275 | - | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | |
| 276 | - | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | |
| 277 | - | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | |
| 278 | - | Some trade or other names: HU-211; | |
| 279 | - | (37) (Blank); | |
| 280 | - | (38) (Blank); | |
| 281 | - | (39) (Blank); | |
| 282 | - | (40) (Blank); | |
| 136 | + | ||
| 137 | + | SB1987 Enrolled - 4 - LRB103 25792 RLC 57149 b | |
| 283 | 138 | ||
| 284 | 139 | ||
| 285 | - | (41) (Blank); | |
| 286 | - | (42) Any compound structurally derived from | |
| 287 | - | 3-(1-naphthoyl)indole or | |
| 288 | - | 1H-indol-3-yl-(1-naphthyl)methane by substitution at the | |
| 289 | - | nitrogen atom of the indole ring by alkyl, haloalkyl, | |
| 290 | - | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 291 | - | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 292 | - | 2-(4-morpholinyl)ethyl whether or not further substituted | |
| 293 | - | in the indole ring to any extent, whether or not | |
| 294 | - | substituted in the naphthyl ring to any extent. Examples | |
| 295 | - | of this structural class include, but are not limited to, | |
| 296 | - | JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | |
| 297 | - | (43) Any compound structurally derived from | |
| 298 | - | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | |
| 299 | - | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | |
| 300 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 301 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 302 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 303 | - | in the pyrrole ring to any extent, whether or not | |
| 304 | - | substituted in the naphthyl ring to any extent. Examples | |
| 305 | - | of this structural class include, but are not limited to, | |
| 306 | - | JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | |
| 307 | - | (44) Any compound structurally derived from | |
| 308 | - | 1-(1-naphthylmethyl)indene by substitution at the | |
| 309 | - | 3-position of the indene ring by alkyl, haloalkyl, | |
| 310 | - | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 140 | + | SB1987 Enrolled- 5 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 5 - LRB103 25792 RLC 57149 b | |
| 141 | + | SB1987 Enrolled - 5 - LRB103 25792 RLC 57149 b | |
| 142 | + | 1 benzenesulfonamide (W-18); | |
| 143 | + | 2 (56) 4-chloro-N-[1-(2-phenylethyl) | |
| 144 | + | 3 -2-piperidinylidene]-benzenesulfonamide (W-15); | |
| 145 | + | 4 (57) acrylfentanyl (acryloylfentanyl). | |
| 146 | + | 5 (c) Unless specifically excepted or unless listed in | |
| 147 | + | 6 another schedule, any of the following opium derivatives, its | |
| 148 | + | 7 salts, isomers and salts of isomers, whenever the existence of | |
| 149 | + | 8 such salts, isomers and salts of isomers is possible within | |
| 150 | + | 9 the specific chemical designation: | |
| 151 | + | 10 (1) Acetorphine; | |
| 152 | + | 11 (2) Acetyldihydrocodeine; | |
| 153 | + | 12 (3) Benzylmorphine; | |
| 154 | + | 13 (4) Codeine methylbromide; | |
| 155 | + | 14 (5) Codeine-N-Oxide; | |
| 156 | + | 15 (6) Cyprenorphine; | |
| 157 | + | 16 (7) Desomorphine; | |
| 158 | + | 17 (8) Diacetyldihydromorphine (Dihydroheroin); | |
| 159 | + | 18 (9) Dihydromorphine; | |
| 160 | + | 19 (10) Drotebanol; | |
| 161 | + | 20 (11) Etorphine (except hydrochloride salt); | |
| 162 | + | 21 (12) Heroin; | |
| 163 | + | 22 (13) Hydromorphinol; | |
| 164 | + | 23 (14) Methyldesorphine; | |
| 165 | + | 24 (15) Methyldihydromorphine; | |
| 166 | + | 25 (16) Morphine methylbromide; | |
| 167 | + | 26 (17) Morphine methylsulfonate; | |
| 311 | 168 | ||
| 312 | 169 | ||
| 313 | - | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 314 | - | 2-(4-morpholinyl)ethyl whether or not further substituted | |
| 315 | - | in the indene ring to any extent, whether or not | |
| 316 | - | substituted in the naphthyl ring to any extent. Examples | |
| 317 | - | of this structural class include, but are not limited to, | |
| 318 | - | JWH-176; | |
| 319 | - | (45) Any compound structurally derived from | |
| 320 | - | 3-phenylacetylindole by substitution at the nitrogen atom | |
| 321 | - | of the indole ring with alkyl, haloalkyl, alkenyl, | |
| 322 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 323 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 324 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 325 | - | in the indole ring to any extent, whether or not | |
| 326 | - | substituted in the phenyl ring to any extent. Examples of | |
| 327 | - | this structural class include, but are not limited to, | |
| 328 | - | JWH-167, JWH-250, JWH-251, and RCS-8; | |
| 329 | - | (46) Any compound structurally derived from | |
| 330 | - | 2-(3-hydroxycyclohexyl)phenol by substitution at the | |
| 331 | - | 5-position of the phenolic ring by alkyl, haloalkyl, | |
| 332 | - | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 333 | - | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 334 | - | 2-(4-morpholinyl)ethyl, whether or not substituted in the | |
| 335 | - | cyclohexyl ring to any extent. Examples of this structural | |
| 336 | - | class include, but are not limited to, CP 47, 497 and its | |
| 337 | - | C8 homologue (cannabicyclohexanol); | |
| 338 | - | (46.1) Any compound structurally derived from | |
| 339 | 170 | ||
| 340 | 171 | ||
| 341 | - | 3-(benzoyl) indole with substitution at the nitrogen atom | |
| 342 | - | of the indole ring by an alkyl, haloalkyl, alkenyl, | |
| 343 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 344 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 345 | - | 2-(4-morpholinyl)ethyl group whether or not further | |
| 346 | - | substituted in the indole ring to any extent and whether | |
| 347 | - | or not substituted in the phenyl ring to any extent. | |
| 348 | - | Examples of this structural class include, but are not | |
| 349 | - | limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN | |
| 350 | - | 48,098), and RCS-4; | |
| 351 | - | (47) (Blank); | |
| 352 | - | (48) (Blank); | |
| 353 | - | (49) (Blank); | |
| 354 | - | (50) (Blank); | |
| 355 | - | (51) (Blank); | |
| 356 | - | (52) (Blank); | |
| 357 | - | (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. | |
| 358 | - | Some trade or other names: 2C-T-7; | |
| 359 | - | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some | |
| 360 | - | trade or other names: 2C-E; | |
| 361 | - | (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some | |
| 362 | - | trade or other names: 2C-D; | |
| 363 | - | (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some | |
| 364 | - | trade or other names: 2C-C; | |
| 365 | - | (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade | |
| 366 | - | or other names: 2C-I; | |
| 172 | + | ||
| 173 | + | SB1987 Enrolled - 5 - LRB103 25792 RLC 57149 b | |
| 367 | 174 | ||
| 368 | 175 | ||
| 369 | - | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some | |
| 370 | - | trade or other names: 2C-T-2; | |
| 371 | - | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. | |
| 372 | - | Some trade or other names: 2C-T-4; | |
| 373 | - | (53.7) 2,5-dimethoxyphenethylamine. Some trade or | |
| 374 | - | other names: 2C-H; | |
| 375 | - | (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some | |
| 376 | - | trade or other names: 2C-N; | |
| 377 | - | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some | |
| 378 | - | trade or other names: 2C-P; | |
| 379 | - | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. | |
| 380 | - | Some trade or other names: 2C-G; | |
| 381 | - | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | |
| 382 | - | phenethylamine referred to in subparagraphs (20.1), (53), | |
| 383 | - | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | |
| 384 | - | (53.8), (53.9), and (53.10) including, but not limited to, | |
| 385 | - | 25I-NBOMe and 25C-NBOMe; | |
| 386 | - | (54) 5-Methoxy-N,N-diisopropyltryptamine; | |
| 387 | - | (55) (Blank); | |
| 388 | - | (56) (Blank); | |
| 389 | - | (57) (Blank); | |
| 390 | - | (58) (Blank); | |
| 391 | - | (59) 3-cyclopropoylindole with substitution at the | |
| 392 | - | nitrogen atom of the indole ring by alkyl, haloalkyl, | |
| 393 | - | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 394 | - | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 176 | + | SB1987 Enrolled- 6 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 6 - LRB103 25792 RLC 57149 b | |
| 177 | + | SB1987 Enrolled - 6 - LRB103 25792 RLC 57149 b | |
| 178 | + | 1 (18) Morphine-N-Oxide; | |
| 179 | + | 2 (19) Myrophine; | |
| 180 | + | 3 (20) Nicocodeine; | |
| 181 | + | 4 (21) Nicomorphine; | |
| 182 | + | 5 (22) Normorphine; | |
| 183 | + | 6 (23) Pholcodine; | |
| 184 | + | 7 (24) Thebacon. | |
| 185 | + | 8 (d) Unless specifically excepted or unless listed in | |
| 186 | + | 9 another schedule, any material, compound, mixture, or | |
| 187 | + | 10 preparation which contains any quantity of the following | |
| 188 | + | 11 hallucinogenic substances, or which contains any of its salts, | |
| 189 | + | 12 isomers and salts of isomers, whenever the existence of such | |
| 190 | + | 13 salts, isomers, and salts of isomers is possible within the | |
| 191 | + | 14 specific chemical designation (for the purposes of this | |
| 192 | + | 15 paragraph only, the term "isomer" includes the optical, | |
| 193 | + | 16 position and geometric isomers): | |
| 194 | + | 17 (1) 3,4-methylenedioxyamphetamine | |
| 195 | + | 18 (alpha-methyl,3,4-methylenedioxyphenethylamine, | |
| 196 | + | 19 methylenedioxyamphetamine, MDA); | |
| 197 | + | 20 (1.1) Alpha-ethyltryptamine | |
| 198 | + | 21 (some trade or other names: etryptamine; | |
| 199 | + | 22 MONASE; alpha-ethyl-1H-indole-3-ethanamine; | |
| 200 | + | 23 3-(2-aminobutyl)indole; a-ET; and AET); | |
| 201 | + | 24 (2) 3,4-methylenedioxymethamphetamine (MDMA); | |
| 202 | + | 25 (2.1) 3,4-methylenedioxy-N-ethylamphetamine | |
| 203 | + | 26 (also known as: N-ethyl-alpha-methyl- | |
| 395 | 204 | ||
| 396 | 205 | ||
| 397 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 398 | - | on the indole ring to any extent, whether or not | |
| 399 | - | substituted on the cyclopropyl ring to any extent: | |
| 400 | - | including, but not limited to, XLR11, UR144, FUB-144; | |
| 401 | - | (60) 3-adamantoylindole with substitution at the | |
| 402 | - | nitrogen atom of the indole ring by alkyl, haloalkyl, | |
| 403 | - | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 404 | - | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 405 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 406 | - | on the indole ring to any extent, whether or not | |
| 407 | - | substituted on the adamantyl ring to any extent: | |
| 408 | - | including, but not limited to, AB-001; | |
| 409 | - | (61) N-(adamantyl)-indole-3-carboxamide with | |
| 410 | - | substitution at the nitrogen atom of the indole ring by | |
| 411 | - | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | |
| 412 | - | cycloalkylethyl, aryl halide, alkyl aryl halide, | |
| 413 | - | 1-(N-methyl-2-piperidinyl)methyl, or | |
| 414 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 415 | - | on the indole ring to any extent, whether or not | |
| 416 | - | substituted on the adamantyl ring to any extent: | |
| 417 | - | including, but not limited to, APICA/2NE-1, STS-135; | |
| 418 | - | (62) N-(adamantyl)-indazole-3-carboxamide with | |
| 419 | - | substitution at a nitrogen atom of the indazole ring by | |
| 420 | - | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | |
| 421 | - | cycloalkylethyl, aryl halide, alkyl aryl halide, | |
| 422 | - | 1-(N-methyl-2-piperidinyl)methyl, or | |
| 423 | 206 | ||
| 424 | 207 | ||
| 425 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 426 | - | on the indazole ring to any extent, whether or not | |
| 427 | - | substituted on the adamantyl ring to any extent: | |
| 428 | - | including, but not limited to, AKB48, 5F-AKB48; | |
| 429 | - | (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester | |
| 430 | - | with substitution at the nitrogen atom of the indole ring | |
| 431 | - | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | |
| 432 | - | cycloalkylethyl, aryl halide, alkyl aryl halide, | |
| 433 | - | 1-(N-methyl-2-piperidinyl)methyl, or | |
| 434 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 435 | - | on the indole ring to any extent, whether or not | |
| 436 | - | substituted on the quinoline ring to any extent: | |
| 437 | - | including, but not limited to, PB22, 5F-PB22, FUB-PB-22; | |
| 438 | - | (64) 3-(1-naphthoyl)indazole with substitution at the | |
| 439 | - | nitrogen atom of the indazole ring by alkyl, haloalkyl, | |
| 440 | - | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 441 | - | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 442 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 443 | - | on the indazole ring to any extent, whether or not | |
| 444 | - | substituted on the naphthyl ring to any extent: including, | |
| 445 | - | but not limited to, THJ-018, THJ-2201; | |
| 446 | - | (65) 2-(1-naphthoyl)benzimidazole with substitution | |
| 447 | - | at the nitrogen atom of the benzimidazole ring by alkyl, | |
| 448 | - | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | |
| 449 | - | aryl halide, alkyl aryl halide, | |
| 450 | - | 1-(N-methyl-2-piperidinyl)methyl, or | |
| 208 | + | ||
| 209 | + | SB1987 Enrolled - 6 - LRB103 25792 RLC 57149 b | |
| 451 | 210 | ||
| 452 | 211 | ||
| 453 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 454 | - | on the benzimidazole ring to any extent, whether or not | |
| 455 | - | substituted on the naphthyl ring to any extent: including, | |
| 456 | - | but not limited to, FUBIMINA; | |
| 457 | - | (66) | |
| 458 | - | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | |
| 459 | - | 3-carboxamide with substitution on the nitrogen atom of | |
| 460 | - | the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 461 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 462 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 463 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 464 | - | on the indazole ring to any extent: including, but not | |
| 465 | - | limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | |
| 466 | - | (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | |
| 467 | - | indazole-3-carboxamide with substitution on the nitrogen | |
| 468 | - | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 469 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 470 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 471 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 472 | - | on the indazole ring to any extent: including, but not | |
| 473 | - | limited to, ADB-PINACA, ADB-FUBINACA; | |
| 474 | - | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | |
| 475 | - | indole-3-carboxamide with substitution on the nitrogen | |
| 476 | - | atom of the indole ring by alkyl, haloalkyl, alkenyl, | |
| 477 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 478 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 212 | + | SB1987 Enrolled- 7 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 7 - LRB103 25792 RLC 57149 b | |
| 213 | + | SB1987 Enrolled - 7 - LRB103 25792 RLC 57149 b | |
| 214 | + | 1 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE, | |
| 215 | + | 2 and MDEA); | |
| 216 | + | 3 (2.2) N-Benzylpiperazine (BZP); | |
| 217 | + | 4 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | |
| 218 | + | 5 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | |
| 219 | + | 6 (4) 3,4,5-trimethoxyamphetamine (TMA); | |
| 220 | + | 7 (5) (Blank); | |
| 221 | + | 8 (6) Diethyltryptamine (DET); | |
| 222 | + | 9 (7) Dimethyltryptamine (DMT); | |
| 223 | + | 10 (7.1) 5-Methoxy-diallyltryptamine; | |
| 224 | + | 11 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | |
| 225 | + | 12 (9) Ibogaine (some trade and other names: | |
| 226 | + | 13 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy- | |
| 227 | + | 14 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b] | |
| 228 | + | 15 indole; Tabernanthe iboga); | |
| 229 | + | 16 (10) Lysergic acid diethylamide; | |
| 230 | + | 17 (10.1) Salvinorin A; | |
| 231 | + | 18 (10.5) Salvia divinorum (meaning all parts of the | |
| 232 | + | 19 plant presently classified botanically as Salvia | |
| 233 | + | 20 divinorum, whether growing or not, the seeds thereof, any | |
| 234 | + | 21 extract from any part of that plant, and every compound, | |
| 235 | + | 22 manufacture, salts, isomers, and salts of isomers whenever | |
| 236 | + | 23 the existence of such salts, isomers, and salts of isomers | |
| 237 | + | 24 is possible within the specific chemical designation, | |
| 238 | + | 25 derivative, mixture, or preparation of that plant, its | |
| 239 | + | 26 seeds or extracts); | |
| 479 | 240 | ||
| 480 | 241 | ||
| 481 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 482 | - | on the indole ring to any extent: including, but not | |
| 483 | - | limited to, ADBICA, 5F-ADBICA; | |
| 484 | - | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | |
| 485 | - | 3-carboxamide with substitution on the nitrogen atom of | |
| 486 | - | the indole ring by alkyl, haloalkyl, alkenyl, | |
| 487 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 488 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 489 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 490 | - | on the indole ring to any extent: including, but not | |
| 491 | - | limited to, ABICA, 5F-ABICA; | |
| 492 | - | (70) Methyl 2-(1H-indazole-3-carboxamido)-3- | |
| 493 | - | methylbutanoate with substitution on the nitrogen atom of | |
| 494 | - | the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 495 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 496 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 497 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 498 | - | on the indazole ring to any extent: including, but not | |
| 499 | - | limited to, AMB, 5F-AMB; | |
| 500 | - | (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- | |
| 501 | - | dimethylbutanoate with substitution on the nitrogen atom | |
| 502 | - | of the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 503 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 504 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 505 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 506 | - | on the indazole ring to any extent: including, but not | |
| 507 | 242 | ||
| 508 | 243 | ||
| 509 | - | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | |
| 510 | - | (72) Methyl 2-(1H-indole-3-carboxamido)-3- | |
| 511 | - | methylbutanoate with substitution on the nitrogen atom of | |
| 512 | - | the indole ring by alkyl, haloalkyl, alkenyl, | |
| 513 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 514 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 515 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 516 | - | on the indazole ring to any extent: including, but not | |
| 517 | - | limited to, MMB018, MMB2201, and AMB-CHMICA; | |
| 518 | - | (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- | |
| 519 | - | dimethylbutanoate with substitution on the nitrogen atom | |
| 520 | - | of the indole ring by alkyl, haloalkyl, alkenyl, | |
| 521 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 522 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 523 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 524 | - | on the indazole ring to any extent: including, but not | |
| 525 | - | limited to, MDMB-CHMICA; | |
| 526 | - | (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | |
| 527 | - | indazole-3-carboxamide with substitution on the nitrogen | |
| 528 | - | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 529 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 530 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 531 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 532 | - | on the indazole ring to any extent: including, but not | |
| 533 | - | limited to, APP-CHMINACA, 5-fluoro-APP-PINACA; | |
| 534 | - | (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- | |
| 244 | + | ||
| 245 | + | SB1987 Enrolled - 7 - LRB103 25792 RLC 57149 b | |
| 535 | 246 | ||
| 536 | 247 | ||
| 537 | - | 3-carboxamide with substitution on the nitrogen atom of | |
| 538 | - | the indole ring by alkyl, haloalkyl, alkenyl, | |
| 539 | - | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 540 | - | halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 541 | - | 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 542 | - | on the indazole ring to any extent: including, but not | |
| 543 | - | limited to, APP-PICA and 5-fluoro-APP-PICA; | |
| 544 | - | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | |
| 545 | - | 4-AcO-DMT; | |
| 546 | - | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | |
| 547 | - | name 5-MeO-MIPT; | |
| 548 | - | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | |
| 549 | - | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | |
| 550 | - | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | |
| 551 | - | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine | |
| 552 | - | (4-HO-MiPT); | |
| 553 | - | (82) Fluorophenylpiperazine; | |
| 554 | - | (83) Methoxetamine; | |
| 555 | - | (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | |
| 556 | - | ethcathinone). | |
| 557 | - | (e) Unless specifically excepted or unless listed in | |
| 558 | - | another schedule, any material, compound, mixture, or | |
| 559 | - | preparation which contains any quantity of the following | |
| 560 | - | substances having a depressant effect on the central nervous | |
| 561 | - | system, including its salts, isomers, and salts of isomers | |
| 562 | - | whenever the existence of such salts, isomers, and salts of | |
| 248 | + | SB1987 Enrolled- 8 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 8 - LRB103 25792 RLC 57149 b | |
| 249 | + | SB1987 Enrolled - 8 - LRB103 25792 RLC 57149 b | |
| 250 | + | 1 (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | |
| 251 | + | 2 (12) Peyote (meaning all parts of the plant presently | |
| 252 | + | 3 classified botanically as Lophophora williamsii Lemaire, | |
| 253 | + | 4 whether growing or not, the seeds thereof, any extract | |
| 254 | + | 5 from any part of that plant, and every compound, | |
| 255 | + | 6 manufacture, salts, derivative, mixture, or preparation of | |
| 256 | + | 7 that plant, its seeds or extracts); | |
| 257 | + | 8 (13) N-ethyl-3-piperidyl benzilate (JB 318); | |
| 258 | + | 9 (14) N-methyl-3-piperidyl benzilate; | |
| 259 | + | 10 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine | |
| 260 | + | 11 (also known as N-hydroxy-alpha-methyl- | |
| 261 | + | 12 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | |
| 262 | + | 13 (15) Parahexyl; some trade or other names: | |
| 263 | + | 14 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- | |
| 264 | + | 15 dibenzo (b,d) pyran; Synhexyl; | |
| 265 | + | 16 (16) Psilocybin; | |
| 266 | + | 17 (17) Psilocyn; | |
| 267 | + | 18 (18) Alpha-methyltryptamine (AMT); | |
| 268 | + | 19 (19) 2,5-dimethoxyamphetamine | |
| 269 | + | 20 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | |
| 270 | + | 21 (20) 4-bromo-2,5-dimethoxyamphetamine | |
| 271 | + | 22 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; | |
| 272 | + | 23 4-bromo-2,5-DMA); | |
| 273 | + | 24 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine. | |
| 274 | + | 25 Some trade or other names: 2-(4-bromo- | |
| 275 | + | 26 2,5-dimethoxyphenyl)-1-aminoethane; | |
| 563 | 276 | ||
| 564 | 277 | ||
| 565 | - | isomers is possible within the specific chemical designation: | |
| 566 | - | (1) mecloqualone; | |
| 567 | - | (2) methaqualone; and | |
| 568 | - | (3) gamma hydroxybutyric acid. | |
| 569 | - | (f) Unless specifically excepted or unless listed in | |
| 570 | - | another schedule, any material, compound, mixture, or | |
| 571 | - | preparation which contains any quantity of the following | |
| 572 | - | substances having a stimulant effect on the central nervous | |
| 573 | - | system, including its salts, isomers, and salts of isomers: | |
| 574 | - | (1) Fenethylline; | |
| 575 | - | (2) N-ethylamphetamine; | |
| 576 | - | (3) Aminorex (some other names: | |
| 577 | - | 2-amino-5-phenyl-2-oxazoline; aminoxaphen; | |
| 578 | - | 4-5-dihydro-5-phenyl-2-oxazolamine) and its | |
| 579 | - | salts, optical isomers, and salts of optical isomers; | |
| 580 | - | (4) Methcathinone (some other names: | |
| 581 | - | 2-methylamino-1-phenylpropan-1-one; | |
| 582 | - | Ephedrone; 2-(methylamino)-propiophenone; | |
| 583 | - | alpha-(methylamino)propiophenone; N-methylcathinone; | |
| 584 | - | methycathinone; Monomethylpropion; UR 1431) and its | |
| 585 | - | salts, optical isomers, and salts of optical isomers; | |
| 586 | - | (5) Cathinone (some trade or other names: | |
| 587 | - | 2-aminopropiophenone; alpha-aminopropiophenone; | |
| 588 | - | 2-amino-1-phenyl-propanone; norephedrone); | |
| 589 | - | (6) N,N-dimethylamphetamine (also known as: | |
| 590 | - | N,N-alpha-trimethyl-benzeneethanamine; | |
| 591 | 278 | ||
| 592 | 279 | ||
| 593 | - | N,N-alpha-trimethylphenethylamine); | |
| 594 | - | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis- | |
| 595 | - | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | |
| 596 | - | (8) 3,4-Methylenedioxypyrovalerone (MDPV); | |
| 597 | - | (9) Halogenated amphetamines and | |
| 598 | - | methamphetamines - any compound derived from either | |
| 599 | - | amphetamine or methamphetamine through the substitution | |
| 600 | - | of a halogen on the phenyl ring, including, but not | |
| 601 | - | limited to, 2-fluoroamphetamine, 3- | |
| 602 | - | fluoroamphetamine and 4-fluoroamphetamine; | |
| 603 | - | (10) Aminopropylbenzofuran (APB): | |
| 604 | - | including 4-(2-Aminopropyl) benzofuran, 5- | |
| 605 | - | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl) | |
| 606 | - | benzofuran, and 7-(2-Aminopropyl) benzofuran; | |
| 607 | - | (11) Aminopropyldihydrobenzofuran (APDB): | |
| 608 | - | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran, | |
| 609 | - | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran, | |
| 610 | - | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, | |
| 611 | - | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | |
| 612 | - | (12) Methylaminopropylbenzofuran | |
| 613 | - | (MAPB): including 4-(2-methylaminopropyl) | |
| 614 | - | benzofuran, 5-(2-methylaminopropyl)benzofuran, | |
| 615 | - | 6-(2-methylaminopropyl)benzofuran | |
| 616 | - | and 7-(2-methylaminopropyl)benzofuran. | |
| 617 | - | (g) Temporary listing of substances subject to emergency | |
| 618 | - | scheduling. Any material, compound, mixture, or preparation | |
| 280 | + | ||
| 281 | + | SB1987 Enrolled - 8 - LRB103 25792 RLC 57149 b | |
| 619 | 282 | ||
| 620 | 283 | ||
| 621 | - | that contains any quantity of the following substances: | |
| 622 | - | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide | |
| 623 | - | (benzylfentanyl), its optical isomers, isomers, salts, and | |
| 624 | - | salts of isomers; | |
| 625 | - | (2) N-[1(2-thienyl) methyl-4-piperidyl]-N- | |
| 626 | - | phenylpropanamide (thenylfentanyl), its optical isomers, | |
| 627 | - | salts, and salts of isomers. | |
| 628 | - | (h) Synthetic cathinones. Unless specifically excepted, | |
| 629 | - | any chemical compound which is not approved by the United | |
| 630 | - | States Food and Drug Administration or, if approved, is not | |
| 631 | - | dispensed or possessed in accordance with State or federal | |
| 632 | - | law, not including bupropion, structurally derived from | |
| 633 | - | 2-aminopropan-1-one by substitution at the 1-position with | |
| 634 | - | either phenyl, naphthyl, or thiophene ring systems, whether or | |
| 635 | - | not the compound is further modified in one or more of the | |
| 636 | - | following ways: | |
| 637 | - | (1) by substitution in the ring system to any extent | |
| 638 | - | with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | |
| 639 | - | halide substituents, whether or not further substituted in | |
| 640 | - | the ring system by one or more other univalent | |
| 641 | - | substituents. Examples of this class include, but are not | |
| 642 | - | limited to, 3,4-Methylenedioxycathinone (bk-MDA); | |
| 643 | - | (2) by substitution at the 3-position with an acyclic | |
| 644 | - | alkyl substituent. Examples of this class include, but are | |
| 645 | - | not limited to, 2-methylamino-1-phenylbutan-1-one | |
| 646 | - | (buphedrone); or | |
| 284 | + | SB1987 Enrolled- 9 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 9 - LRB103 25792 RLC 57149 b | |
| 285 | + | SB1987 Enrolled - 9 - LRB103 25792 RLC 57149 b | |
| 286 | + | 1 alpha-desmethyl DOB, 2CB, Nexus; | |
| 287 | + | 2 (21) 4-methoxyamphetamine | |
| 288 | + | 3 (4-methoxy-alpha-methylphenethylamine; | |
| 289 | + | 4 paramethoxyamphetamine; PMA); | |
| 290 | + | 5 (22) (Blank); | |
| 291 | + | 6 (23) Ethylamine analog of phencyclidine. | |
| 292 | + | 7 Some trade or other names: | |
| 293 | + | 8 N-ethyl-1-phenylcyclohexylamine, | |
| 294 | + | 9 (1-phenylcyclohexyl) ethylamine, | |
| 295 | + | 10 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | |
| 296 | + | 11 (24) Pyrrolidine analog of phencyclidine. Some trade | |
| 297 | + | 12 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | |
| 298 | + | 13 PHP; | |
| 299 | + | 14 (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | |
| 300 | + | 15 (26) 2,5-dimethoxy-4-ethylamphetamine | |
| 301 | + | 16 (another name: DOET); | |
| 302 | + | 17 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine | |
| 303 | + | 18 (another name: TCPy); | |
| 304 | + | 19 (28) (Blank); | |
| 305 | + | 20 (29) Thiophene analog of phencyclidine (some trade | |
| 306 | + | 21 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; | |
| 307 | + | 22 2-thienyl analog of phencyclidine; TPCP; TCP); | |
| 308 | + | 23 (29.1) Benzothiophene analog of phencyclidine. Some | |
| 309 | + | 24 trade or other names: BTCP or benocyclidine; | |
| 310 | + | 25 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); | |
| 311 | + | 26 (30) Bufotenine (some trade or other names: | |
| 647 | 312 | ||
| 648 | 313 | ||
| 649 | - | (3) by substitution at the 2-amino nitrogen atom with | |
| 650 | - | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by | |
| 651 | - | inclusion of the 2-amino nitrogen atom in a cyclic | |
| 652 | - | structure. Examples of this class include, but are not | |
| 653 | - | limited to, Dimethylcathinone, Ethcathinone, and | |
| 654 | - | a-Pyrrolidinopropiophenone (a-PPP); or | |
| 655 | - | Any other synthetic cathinone which is not approved by the | |
| 656 | - | United States Food and Drug Administration or, if approved, is | |
| 657 | - | not dispensed or possessed in accordance with State or federal | |
| 658 | - | law. | |
| 659 | - | (i) Synthetic cannabinoids or piperazines. Any synthetic | |
| 660 | - | cannabinoid or piperazine which is not approved by the United | |
| 661 | - | States Food and Drug Administration or, if approved, which is | |
| 662 | - | not dispensed or possessed in accordance with State and | |
| 663 | - | federal law. | |
| 664 | - | (j) Unless specifically excepted or listed in another | |
| 665 | - | schedule, any chemical compound which is not approved by the | |
| 666 | - | United States Food and Drug Administration or, if approved, is | |
| 667 | - | not dispensed or possessed in accordance with State or federal | |
| 668 | - | law, and is derived from the following structural classes and | |
| 669 | - | their salts: | |
| 670 | - | (1) Benzodiazepine class: A fused 1,4-diazepine and | |
| 671 | - | benzene ring structure with a phenyl connected to the | |
| 672 | - | 1,4-diazepine ring, with any substitution(s) or | |
| 673 | - | replacement(s) on the 1,4-diazepine or benzene ring, any | |
| 674 | - | substitution(s) on the phenyl ring, or any combination | |
| 675 | 314 | ||
| 676 | 315 | ||
| 677 | - | thereof. Examples of this class include but are not | |
| 678 | - | limited to: Clonazolam, Flualprazolam; or | |
| 679 | - | (2) Thienodiazepine class: A fused 1,4-diazepine and | |
| 680 | - | thiophene ring structure with a phenyl connected to the | |
| 681 | - | 1,4-diazepine ring, with any substitution(s) or | |
| 682 | - | replacement(s) on the 1,4-diazepine or thiophene ring, any | |
| 683 | - | substitution(s) on the phenyl ring, or any combination | |
| 684 | - | thereof. Examples of this class include but are not | |
| 685 | - | limited to: Etizolam. | |
| 686 | - | (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; | |
| 687 | - | 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. | |
| 688 | - | 8-14-18.) | |
| 316 | + | ||
| 317 | + | SB1987 Enrolled - 9 - LRB103 25792 RLC 57149 b | |
| 318 | + | ||
| 319 | + | ||
| 320 | + | SB1987 Enrolled- 10 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 10 - LRB103 25792 RLC 57149 b | |
| 321 | + | SB1987 Enrolled - 10 - LRB103 25792 RLC 57149 b | |
| 322 | + | 1 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole; | |
| 323 | + | 2 3-(2-dimethylaminoethyl)-5-indolol; | |
| 324 | + | 3 5-hydroxy-N,N-dimethyltryptamine; | |
| 325 | + | 4 N,N-dimethylserotonin; mappine); | |
| 326 | + | 5 (31) (Blank); | |
| 327 | + | 6 (32) (Blank); | |
| 328 | + | 7 (33) (Blank); | |
| 329 | + | 8 (34) (Blank); | |
| 330 | + | 9 (34.5) (Blank); | |
| 331 | + | 10 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | |
| 332 | + | 11 (2-methyloctan-2-yl)-6a,7, | |
| 333 | + | 12 10,10a-tetrahydrobenzo[c]chromen-1-ol | |
| 334 | + | 13 Some trade or other names: HU-210; | |
| 335 | + | 14 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | |
| 336 | + | 15 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | |
| 337 | + | 16 tetrahydrobenzo[c]chromen-1-ol, its isomers, | |
| 338 | + | 17 salts, and salts of isomers; Some trade or other | |
| 339 | + | 18 names: HU-210, Dexanabinol; | |
| 340 | + | 19 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | |
| 341 | + | 20 6,6-dimethyl-3-(2-methyloctan-2-yl)- | |
| 342 | + | 21 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | |
| 343 | + | 22 Some trade or other names: HU-211; | |
| 344 | + | 23 (37) (Blank); | |
| 345 | + | 24 (38) (Blank); | |
| 346 | + | 25 (39) (Blank); | |
| 347 | + | 26 (40) (Blank); | |
| 348 | + | ||
| 349 | + | ||
| 350 | + | ||
| 351 | + | ||
| 352 | + | ||
| 353 | + | SB1987 Enrolled - 10 - LRB103 25792 RLC 57149 b | |
| 354 | + | ||
| 355 | + | ||
| 356 | + | SB1987 Enrolled- 11 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 11 - LRB103 25792 RLC 57149 b | |
| 357 | + | SB1987 Enrolled - 11 - LRB103 25792 RLC 57149 b | |
| 358 | + | 1 (41) (Blank); | |
| 359 | + | 2 (42) Any compound structurally derived from | |
| 360 | + | 3 3-(1-naphthoyl)indole or | |
| 361 | + | 4 1H-indol-3-yl-(1-naphthyl)methane by substitution at the | |
| 362 | + | 5 nitrogen atom of the indole ring by alkyl, haloalkyl, | |
| 363 | + | 6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 364 | + | 7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 365 | + | 8 2-(4-morpholinyl)ethyl whether or not further substituted | |
| 366 | + | 9 in the indole ring to any extent, whether or not | |
| 367 | + | 10 substituted in the naphthyl ring to any extent. Examples | |
| 368 | + | 11 of this structural class include, but are not limited to, | |
| 369 | + | 12 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | |
| 370 | + | 13 (43) Any compound structurally derived from | |
| 371 | + | 14 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | |
| 372 | + | 15 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | |
| 373 | + | 16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 374 | + | 17 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 375 | + | 18 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 376 | + | 19 in the pyrrole ring to any extent, whether or not | |
| 377 | + | 20 substituted in the naphthyl ring to any extent. Examples | |
| 378 | + | 21 of this structural class include, but are not limited to, | |
| 379 | + | 22 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | |
| 380 | + | 23 (44) Any compound structurally derived from | |
| 381 | + | 24 1-(1-naphthylmethyl)indene by substitution at the | |
| 382 | + | 25 3-position of the indene ring by alkyl, haloalkyl, | |
| 383 | + | 26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 384 | + | ||
| 385 | + | ||
| 386 | + | ||
| 387 | + | ||
| 388 | + | ||
| 389 | + | SB1987 Enrolled - 11 - LRB103 25792 RLC 57149 b | |
| 390 | + | ||
| 391 | + | ||
| 392 | + | SB1987 Enrolled- 12 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 12 - LRB103 25792 RLC 57149 b | |
| 393 | + | SB1987 Enrolled - 12 - LRB103 25792 RLC 57149 b | |
| 394 | + | 1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 395 | + | 2 2-(4-morpholinyl)ethyl whether or not further substituted | |
| 396 | + | 3 in the indene ring to any extent, whether or not | |
| 397 | + | 4 substituted in the naphthyl ring to any extent. Examples | |
| 398 | + | 5 of this structural class include, but are not limited to, | |
| 399 | + | 6 JWH-176; | |
| 400 | + | 7 (45) Any compound structurally derived from | |
| 401 | + | 8 3-phenylacetylindole by substitution at the nitrogen atom | |
| 402 | + | 9 of the indole ring with alkyl, haloalkyl, alkenyl, | |
| 403 | + | 10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 404 | + | 11 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 405 | + | 12 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 406 | + | 13 in the indole ring to any extent, whether or not | |
| 407 | + | 14 substituted in the phenyl ring to any extent. Examples of | |
| 408 | + | 15 this structural class include, but are not limited to, | |
| 409 | + | 16 JWH-167, JWH-250, JWH-251, and RCS-8; | |
| 410 | + | 17 (46) Any compound structurally derived from | |
| 411 | + | 18 2-(3-hydroxycyclohexyl)phenol by substitution at the | |
| 412 | + | 19 5-position of the phenolic ring by alkyl, haloalkyl, | |
| 413 | + | 20 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 414 | + | 21 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 415 | + | 22 2-(4-morpholinyl)ethyl, whether or not substituted in the | |
| 416 | + | 23 cyclohexyl ring to any extent. Examples of this structural | |
| 417 | + | 24 class include, but are not limited to, CP 47, 497 and its | |
| 418 | + | 25 C8 homologue (cannabicyclohexanol); | |
| 419 | + | 26 (46.1) Any compound structurally derived from | |
| 420 | + | ||
| 421 | + | ||
| 422 | + | ||
| 423 | + | ||
| 424 | + | ||
| 425 | + | SB1987 Enrolled - 12 - LRB103 25792 RLC 57149 b | |
| 426 | + | ||
| 427 | + | ||
| 428 | + | SB1987 Enrolled- 13 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 13 - LRB103 25792 RLC 57149 b | |
| 429 | + | SB1987 Enrolled - 13 - LRB103 25792 RLC 57149 b | |
| 430 | + | 1 3-(benzoyl) indole with substitution at the nitrogen atom | |
| 431 | + | 2 of the indole ring by an alkyl, haloalkyl, alkenyl, | |
| 432 | + | 3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 433 | + | 4 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 434 | + | 5 2-(4-morpholinyl)ethyl group whether or not further | |
| 435 | + | 6 substituted in the indole ring to any extent and whether | |
| 436 | + | 7 or not substituted in the phenyl ring to any extent. | |
| 437 | + | 8 Examples of this structural class include, but are not | |
| 438 | + | 9 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN | |
| 439 | + | 10 48,098), and RCS-4; | |
| 440 | + | 11 (47) (Blank); | |
| 441 | + | 12 (48) (Blank); | |
| 442 | + | 13 (49) (Blank); | |
| 443 | + | 14 (50) (Blank); | |
| 444 | + | 15 (51) (Blank); | |
| 445 | + | 16 (52) (Blank); | |
| 446 | + | 17 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. | |
| 447 | + | 18 Some trade or other names: 2C-T-7; | |
| 448 | + | 19 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some | |
| 449 | + | 20 trade or other names: 2C-E; | |
| 450 | + | 21 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some | |
| 451 | + | 22 trade or other names: 2C-D; | |
| 452 | + | 23 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some | |
| 453 | + | 24 trade or other names: 2C-C; | |
| 454 | + | 25 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade | |
| 455 | + | 26 or other names: 2C-I; | |
| 456 | + | ||
| 457 | + | ||
| 458 | + | ||
| 459 | + | ||
| 460 | + | ||
| 461 | + | SB1987 Enrolled - 13 - LRB103 25792 RLC 57149 b | |
| 462 | + | ||
| 463 | + | ||
| 464 | + | SB1987 Enrolled- 14 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 14 - LRB103 25792 RLC 57149 b | |
| 465 | + | SB1987 Enrolled - 14 - LRB103 25792 RLC 57149 b | |
| 466 | + | 1 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some | |
| 467 | + | 2 trade or other names: 2C-T-2; | |
| 468 | + | 3 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. | |
| 469 | + | 4 Some trade or other names: 2C-T-4; | |
| 470 | + | 5 (53.7) 2,5-dimethoxyphenethylamine. Some trade or | |
| 471 | + | 6 other names: 2C-H; | |
| 472 | + | 7 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some | |
| 473 | + | 8 trade or other names: 2C-N; | |
| 474 | + | 9 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some | |
| 475 | + | 10 trade or other names: 2C-P; | |
| 476 | + | 11 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. | |
| 477 | + | 12 Some trade or other names: 2C-G; | |
| 478 | + | 13 (53.11) The N-(2-methoxybenzyl) derivative of any 2C | |
| 479 | + | 14 phenethylamine referred to in subparagraphs (20.1), (53), | |
| 480 | + | 15 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | |
| 481 | + | 16 (53.8), (53.9), and (53.10) including, but not limited to, | |
| 482 | + | 17 25I-NBOMe and 25C-NBOMe; | |
| 483 | + | 18 (54) 5-Methoxy-N,N-diisopropyltryptamine; | |
| 484 | + | 19 (55) (Blank); | |
| 485 | + | 20 (56) (Blank); | |
| 486 | + | 21 (57) (Blank); | |
| 487 | + | 22 (58) (Blank); | |
| 488 | + | 23 (59) 3-cyclopropoylindole with substitution at the | |
| 489 | + | 24 nitrogen atom of the indole ring by alkyl, haloalkyl, | |
| 490 | + | 25 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 491 | + | 26 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 492 | + | ||
| 493 | + | ||
| 494 | + | ||
| 495 | + | ||
| 496 | + | ||
| 497 | + | SB1987 Enrolled - 14 - LRB103 25792 RLC 57149 b | |
| 498 | + | ||
| 499 | + | ||
| 500 | + | SB1987 Enrolled- 15 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 15 - LRB103 25792 RLC 57149 b | |
| 501 | + | SB1987 Enrolled - 15 - LRB103 25792 RLC 57149 b | |
| 502 | + | 1 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 503 | + | 2 on the indole ring to any extent, whether or not | |
| 504 | + | 3 substituted on the cyclopropyl ring to any extent: | |
| 505 | + | 4 including, but not limited to, XLR11, UR144, FUB-144; | |
| 506 | + | 5 (60) 3-adamantoylindole with substitution at the | |
| 507 | + | 6 nitrogen atom of the indole ring by alkyl, haloalkyl, | |
| 508 | + | 7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 509 | + | 8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 510 | + | 9 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 511 | + | 10 on the indole ring to any extent, whether or not | |
| 512 | + | 11 substituted on the adamantyl ring to any extent: | |
| 513 | + | 12 including, but not limited to, AB-001; | |
| 514 | + | 13 (61) N-(adamantyl)-indole-3-carboxamide with | |
| 515 | + | 14 substitution at the nitrogen atom of the indole ring by | |
| 516 | + | 15 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | |
| 517 | + | 16 cycloalkylethyl, aryl halide, alkyl aryl halide, | |
| 518 | + | 17 1-(N-methyl-2-piperidinyl)methyl, or | |
| 519 | + | 18 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 520 | + | 19 on the indole ring to any extent, whether or not | |
| 521 | + | 20 substituted on the adamantyl ring to any extent: | |
| 522 | + | 21 including, but not limited to, APICA/2NE-1, STS-135; | |
| 523 | + | 22 (62) N-(adamantyl)-indazole-3-carboxamide with | |
| 524 | + | 23 substitution at a nitrogen atom of the indazole ring by | |
| 525 | + | 24 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | |
| 526 | + | 25 cycloalkylethyl, aryl halide, alkyl aryl halide, | |
| 527 | + | 26 1-(N-methyl-2-piperidinyl)methyl, or | |
| 528 | + | ||
| 529 | + | ||
| 530 | + | ||
| 531 | + | ||
| 532 | + | ||
| 533 | + | SB1987 Enrolled - 15 - LRB103 25792 RLC 57149 b | |
| 534 | + | ||
| 535 | + | ||
| 536 | + | SB1987 Enrolled- 16 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 16 - LRB103 25792 RLC 57149 b | |
| 537 | + | SB1987 Enrolled - 16 - LRB103 25792 RLC 57149 b | |
| 538 | + | 1 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 539 | + | 2 on the indazole ring to any extent, whether or not | |
| 540 | + | 3 substituted on the adamantyl ring to any extent: | |
| 541 | + | 4 including, but not limited to, AKB48, 5F-AKB48; | |
| 542 | + | 5 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester | |
| 543 | + | 6 with substitution at the nitrogen atom of the indole ring | |
| 544 | + | 7 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | |
| 545 | + | 8 cycloalkylethyl, aryl halide, alkyl aryl halide, | |
| 546 | + | 9 1-(N-methyl-2-piperidinyl)methyl, or | |
| 547 | + | 10 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 548 | + | 11 on the indole ring to any extent, whether or not | |
| 549 | + | 12 substituted on the quinoline ring to any extent: | |
| 550 | + | 13 including, but not limited to, PB22, 5F-PB22, FUB-PB-22; | |
| 551 | + | 14 (64) 3-(1-naphthoyl)indazole with substitution at the | |
| 552 | + | 15 nitrogen atom of the indazole ring by alkyl, haloalkyl, | |
| 553 | + | 16 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | |
| 554 | + | 17 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 555 | + | 18 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 556 | + | 19 on the indazole ring to any extent, whether or not | |
| 557 | + | 20 substituted on the naphthyl ring to any extent: including, | |
| 558 | + | 21 but not limited to, THJ-018, THJ-2201; | |
| 559 | + | 22 (65) 2-(1-naphthoyl)benzimidazole with substitution | |
| 560 | + | 23 at the nitrogen atom of the benzimidazole ring by alkyl, | |
| 561 | + | 24 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | |
| 562 | + | 25 aryl halide, alkyl aryl halide, | |
| 563 | + | 26 1-(N-methyl-2-piperidinyl)methyl, or | |
| 564 | + | ||
| 565 | + | ||
| 566 | + | ||
| 567 | + | ||
| 568 | + | ||
| 569 | + | SB1987 Enrolled - 16 - LRB103 25792 RLC 57149 b | |
| 570 | + | ||
| 571 | + | ||
| 572 | + | SB1987 Enrolled- 17 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 17 - LRB103 25792 RLC 57149 b | |
| 573 | + | SB1987 Enrolled - 17 - LRB103 25792 RLC 57149 b | |
| 574 | + | 1 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 575 | + | 2 on the benzimidazole ring to any extent, whether or not | |
| 576 | + | 3 substituted on the naphthyl ring to any extent: including, | |
| 577 | + | 4 but not limited to, FUBIMINA; | |
| 578 | + | 5 (66) | |
| 579 | + | 6 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | |
| 580 | + | 7 3-carboxamide with substitution on the nitrogen atom of | |
| 581 | + | 8 the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 582 | + | 9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 583 | + | 10 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 584 | + | 11 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 585 | + | 12 on the indazole ring to any extent: including, but not | |
| 586 | + | 13 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | |
| 587 | + | 14 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | |
| 588 | + | 15 indazole-3-carboxamide with substitution on the nitrogen | |
| 589 | + | 16 atom of the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 590 | + | 17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 591 | + | 18 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 592 | + | 19 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 593 | + | 20 on the indazole ring to any extent: including, but not | |
| 594 | + | 21 limited to, ADB-PINACA, ADB-FUBINACA; | |
| 595 | + | 22 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | |
| 596 | + | 23 indole-3-carboxamide with substitution on the nitrogen | |
| 597 | + | 24 atom of the indole ring by alkyl, haloalkyl, alkenyl, | |
| 598 | + | 25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 599 | + | 26 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 600 | + | ||
| 601 | + | ||
| 602 | + | ||
| 603 | + | ||
| 604 | + | ||
| 605 | + | SB1987 Enrolled - 17 - LRB103 25792 RLC 57149 b | |
| 606 | + | ||
| 607 | + | ||
| 608 | + | SB1987 Enrolled- 18 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 18 - LRB103 25792 RLC 57149 b | |
| 609 | + | SB1987 Enrolled - 18 - LRB103 25792 RLC 57149 b | |
| 610 | + | 1 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 611 | + | 2 on the indole ring to any extent: including, but not | |
| 612 | + | 3 limited to, ADBICA, 5F-ADBICA; | |
| 613 | + | 4 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | |
| 614 | + | 5 3-carboxamide with substitution on the nitrogen atom of | |
| 615 | + | 6 the indole ring by alkyl, haloalkyl, alkenyl, | |
| 616 | + | 7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 617 | + | 8 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 618 | + | 9 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 619 | + | 10 on the indole ring to any extent: including, but not | |
| 620 | + | 11 limited to, ABICA, 5F-ABICA; | |
| 621 | + | 12 (70) Methyl 2-(1H-indazole-3-carboxamido)-3- | |
| 622 | + | 13 methylbutanoate with substitution on the nitrogen atom of | |
| 623 | + | 14 the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 624 | + | 15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 625 | + | 16 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 626 | + | 17 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 627 | + | 18 on the indazole ring to any extent: including, but not | |
| 628 | + | 19 limited to, AMB, 5F-AMB; | |
| 629 | + | 20 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- | |
| 630 | + | 21 dimethylbutanoate with substitution on the nitrogen atom | |
| 631 | + | 22 of the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 632 | + | 23 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 633 | + | 24 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 634 | + | 25 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 635 | + | 26 on the indazole ring to any extent: including, but not | |
| 636 | + | ||
| 637 | + | ||
| 638 | + | ||
| 639 | + | ||
| 640 | + | ||
| 641 | + | SB1987 Enrolled - 18 - LRB103 25792 RLC 57149 b | |
| 642 | + | ||
| 643 | + | ||
| 644 | + | SB1987 Enrolled- 19 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 19 - LRB103 25792 RLC 57149 b | |
| 645 | + | SB1987 Enrolled - 19 - LRB103 25792 RLC 57149 b | |
| 646 | + | 1 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | |
| 647 | + | 2 (72) Methyl 2-(1H-indole-3-carboxamido)-3- | |
| 648 | + | 3 methylbutanoate with substitution on the nitrogen atom of | |
| 649 | + | 4 the indole ring by alkyl, haloalkyl, alkenyl, | |
| 650 | + | 5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 651 | + | 6 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 652 | + | 7 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 653 | + | 8 on the indazole ring to any extent: including, but not | |
| 654 | + | 9 limited to, MMB018, MMB2201, and AMB-CHMICA; | |
| 655 | + | 10 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- | |
| 656 | + | 11 dimethylbutanoate with substitution on the nitrogen atom | |
| 657 | + | 12 of the indole ring by alkyl, haloalkyl, alkenyl, | |
| 658 | + | 13 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 659 | + | 14 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 660 | + | 15 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 661 | + | 16 on the indazole ring to any extent: including, but not | |
| 662 | + | 17 limited to, MDMB-CHMICA; | |
| 663 | + | 18 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | |
| 664 | + | 19 indazole-3-carboxamide with substitution on the nitrogen | |
| 665 | + | 20 atom of the indazole ring by alkyl, haloalkyl, alkenyl, | |
| 666 | + | 21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 667 | + | 22 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 668 | + | 23 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 669 | + | 24 on the indazole ring to any extent: including, but not | |
| 670 | + | 25 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA; | |
| 671 | + | 26 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- | |
| 672 | + | ||
| 673 | + | ||
| 674 | + | ||
| 675 | + | ||
| 676 | + | ||
| 677 | + | SB1987 Enrolled - 19 - LRB103 25792 RLC 57149 b | |
| 678 | + | ||
| 679 | + | ||
| 680 | + | SB1987 Enrolled- 20 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 20 - LRB103 25792 RLC 57149 b | |
| 681 | + | SB1987 Enrolled - 20 - LRB103 25792 RLC 57149 b | |
| 682 | + | 1 3-carboxamide with substitution on the nitrogen atom of | |
| 683 | + | 2 the indole ring by alkyl, haloalkyl, alkenyl, | |
| 684 | + | 3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | |
| 685 | + | 4 halide, 1-(N-methyl-2-piperidinyl)methyl, or | |
| 686 | + | 5 2-(4-morpholinyl)ethyl, whether or not further substituted | |
| 687 | + | 6 on the indazole ring to any extent: including, but not | |
| 688 | + | 7 limited to, APP-PICA and 5-fluoro-APP-PICA; | |
| 689 | + | 8 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | |
| 690 | + | 9 4-AcO-DMT; | |
| 691 | + | 10 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | |
| 692 | + | 11 name 5-MeO-MIPT; | |
| 693 | + | 12 (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | |
| 694 | + | 13 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | |
| 695 | + | 14 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | |
| 696 | + | 15 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine | |
| 697 | + | 16 (4-HO-MiPT); | |
| 698 | + | 17 (82) Fluorophenylpiperazine; | |
| 699 | + | 18 (83) Methoxetamine; | |
| 700 | + | 19 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | |
| 701 | + | 20 ethcathinone). | |
| 702 | + | 21 (e) Unless specifically excepted or unless listed in | |
| 703 | + | 22 another schedule, any material, compound, mixture, or | |
| 704 | + | 23 preparation which contains any quantity of the following | |
| 705 | + | 24 substances having a depressant effect on the central nervous | |
| 706 | + | 25 system, including its salts, isomers, and salts of isomers | |
| 707 | + | 26 whenever the existence of such salts, isomers, and salts of | |
| 708 | + | ||
| 709 | + | ||
| 710 | + | ||
| 711 | + | ||
| 712 | + | ||
| 713 | + | SB1987 Enrolled - 20 - LRB103 25792 RLC 57149 b | |
| 714 | + | ||
| 715 | + | ||
| 716 | + | SB1987 Enrolled- 21 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 21 - LRB103 25792 RLC 57149 b | |
| 717 | + | SB1987 Enrolled - 21 - LRB103 25792 RLC 57149 b | |
| 718 | + | 1 isomers is possible within the specific chemical designation: | |
| 719 | + | 2 (1) mecloqualone; | |
| 720 | + | 3 (2) methaqualone; and | |
| 721 | + | 4 (3) gamma hydroxybutyric acid. | |
| 722 | + | 5 (f) Unless specifically excepted or unless listed in | |
| 723 | + | 6 another schedule, any material, compound, mixture, or | |
| 724 | + | 7 preparation which contains any quantity of the following | |
| 725 | + | 8 substances having a stimulant effect on the central nervous | |
| 726 | + | 9 system, including its salts, isomers, and salts of isomers: | |
| 727 | + | 10 (1) Fenethylline; | |
| 728 | + | 11 (2) N-ethylamphetamine; | |
| 729 | + | 12 (3) Aminorex (some other names: | |
| 730 | + | 13 2-amino-5-phenyl-2-oxazoline; aminoxaphen; | |
| 731 | + | 14 4-5-dihydro-5-phenyl-2-oxazolamine) and its | |
| 732 | + | 15 salts, optical isomers, and salts of optical isomers; | |
| 733 | + | 16 (4) Methcathinone (some other names: | |
| 734 | + | 17 2-methylamino-1-phenylpropan-1-one; | |
| 735 | + | 18 Ephedrone; 2-(methylamino)-propiophenone; | |
| 736 | + | 19 alpha-(methylamino)propiophenone; N-methylcathinone; | |
| 737 | + | 20 methycathinone; Monomethylpropion; UR 1431) and its | |
| 738 | + | 21 salts, optical isomers, and salts of optical isomers; | |
| 739 | + | 22 (5) Cathinone (some trade or other names: | |
| 740 | + | 23 2-aminopropiophenone; alpha-aminopropiophenone; | |
| 741 | + | 24 2-amino-1-phenyl-propanone; norephedrone); | |
| 742 | + | 25 (6) N,N-dimethylamphetamine (also known as: | |
| 743 | + | 26 N,N-alpha-trimethyl-benzeneethanamine; | |
| 744 | + | ||
| 745 | + | ||
| 746 | + | ||
| 747 | + | ||
| 748 | + | ||
| 749 | + | SB1987 Enrolled - 21 - LRB103 25792 RLC 57149 b | |
| 750 | + | ||
| 751 | + | ||
| 752 | + | SB1987 Enrolled- 22 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 22 - LRB103 25792 RLC 57149 b | |
| 753 | + | SB1987 Enrolled - 22 - LRB103 25792 RLC 57149 b | |
| 754 | + | 1 N,N-alpha-trimethylphenethylamine); | |
| 755 | + | 2 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis- | |
| 756 | + | 3 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | |
| 757 | + | 4 (8) 3,4-Methylenedioxypyrovalerone (MDPV); | |
| 758 | + | 5 (9) Halogenated amphetamines and | |
| 759 | + | 6 methamphetamines - any compound derived from either | |
| 760 | + | 7 amphetamine or methamphetamine through the substitution | |
| 761 | + | 8 of a halogen on the phenyl ring, including, but not | |
| 762 | + | 9 limited to, 2-fluoroamphetamine, 3- | |
| 763 | + | 10 fluoroamphetamine and 4-fluoroamphetamine; | |
| 764 | + | 11 (10) Aminopropylbenzofuran (APB): | |
| 765 | + | 12 including 4-(2-Aminopropyl) benzofuran, 5- | |
| 766 | + | 13 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl) | |
| 767 | + | 14 benzofuran, and 7-(2-Aminopropyl) benzofuran; | |
| 768 | + | 15 (11) Aminopropyldihydrobenzofuran (APDB): | |
| 769 | + | 16 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran, | |
| 770 | + | 17 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran, | |
| 771 | + | 18 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, | |
| 772 | + | 19 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | |
| 773 | + | 20 (12) Methylaminopropylbenzofuran | |
| 774 | + | 21 (MAPB): including 4-(2-methylaminopropyl) | |
| 775 | + | 22 benzofuran, 5-(2-methylaminopropyl)benzofuran, | |
| 776 | + | 23 6-(2-methylaminopropyl)benzofuran | |
| 777 | + | 24 and 7-(2-methylaminopropyl)benzofuran. | |
| 778 | + | 25 (g) Temporary listing of substances subject to emergency | |
| 779 | + | 26 scheduling. Any material, compound, mixture, or preparation | |
| 780 | + | ||
| 781 | + | ||
| 782 | + | ||
| 783 | + | ||
| 784 | + | ||
| 785 | + | SB1987 Enrolled - 22 - LRB103 25792 RLC 57149 b | |
| 786 | + | ||
| 787 | + | ||
| 788 | + | SB1987 Enrolled- 23 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 23 - LRB103 25792 RLC 57149 b | |
| 789 | + | SB1987 Enrolled - 23 - LRB103 25792 RLC 57149 b | |
| 790 | + | 1 that contains any quantity of the following substances: | |
| 791 | + | 2 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide | |
| 792 | + | 3 (benzylfentanyl), its optical isomers, isomers, salts, and | |
| 793 | + | 4 salts of isomers; | |
| 794 | + | 5 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N- | |
| 795 | + | 6 phenylpropanamide (thenylfentanyl), its optical isomers, | |
| 796 | + | 7 salts, and salts of isomers. | |
| 797 | + | 8 (h) Synthetic cathinones. Unless specifically excepted, | |
| 798 | + | 9 any chemical compound which is not approved by the United | |
| 799 | + | 10 States Food and Drug Administration or, if approved, is not | |
| 800 | + | 11 dispensed or possessed in accordance with State or federal | |
| 801 | + | 12 law, not including bupropion, structurally derived from | |
| 802 | + | 13 2-aminopropan-1-one by substitution at the 1-position with | |
| 803 | + | 14 either phenyl, naphthyl, or thiophene ring systems, whether or | |
| 804 | + | 15 not the compound is further modified in one or more of the | |
| 805 | + | 16 following ways: | |
| 806 | + | 17 (1) by substitution in the ring system to any extent | |
| 807 | + | 18 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | |
| 808 | + | 19 halide substituents, whether or not further substituted in | |
| 809 | + | 20 the ring system by one or more other univalent | |
| 810 | + | 21 substituents. Examples of this class include, but are not | |
| 811 | + | 22 limited to, 3,4-Methylenedioxycathinone (bk-MDA); | |
| 812 | + | 23 (2) by substitution at the 3-position with an acyclic | |
| 813 | + | 24 alkyl substituent. Examples of this class include, but are | |
| 814 | + | 25 not limited to, 2-methylamino-1-phenylbutan-1-one | |
| 815 | + | 26 (buphedrone); or | |
| 816 | + | ||
| 817 | + | ||
| 818 | + | ||
| 819 | + | ||
| 820 | + | ||
| 821 | + | SB1987 Enrolled - 23 - LRB103 25792 RLC 57149 b | |
| 822 | + | ||
| 823 | + | ||
| 824 | + | SB1987 Enrolled- 24 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 24 - LRB103 25792 RLC 57149 b | |
| 825 | + | SB1987 Enrolled - 24 - LRB103 25792 RLC 57149 b | |
| 826 | + | 1 (3) by substitution at the 2-amino nitrogen atom with | |
| 827 | + | 2 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by | |
| 828 | + | 3 inclusion of the 2-amino nitrogen atom in a cyclic | |
| 829 | + | 4 structure. Examples of this class include, but are not | |
| 830 | + | 5 limited to, Dimethylcathinone, Ethcathinone, and | |
| 831 | + | 6 a-Pyrrolidinopropiophenone (a-PPP); or | |
| 832 | + | 7 Any other synthetic cathinone which is not approved by the | |
| 833 | + | 8 United States Food and Drug Administration or, if approved, is | |
| 834 | + | 9 not dispensed or possessed in accordance with State or federal | |
| 835 | + | 10 law. | |
| 836 | + | 11 (i) Synthetic cannabinoids or piperazines. Any synthetic | |
| 837 | + | 12 cannabinoid or piperazine which is not approved by the United | |
| 838 | + | 13 States Food and Drug Administration or, if approved, which is | |
| 839 | + | 14 not dispensed or possessed in accordance with State and | |
| 840 | + | 15 federal law. | |
| 841 | + | 16 (j) Unless specifically excepted or listed in another | |
| 842 | + | 17 schedule, any chemical compound which is not approved by the | |
| 843 | + | 18 United States Food and Drug Administration or, if approved, is | |
| 844 | + | 19 not dispensed or possessed in accordance with State or federal | |
| 845 | + | 20 law, and is derived from the following structural classes and | |
| 846 | + | 21 their salts: | |
| 847 | + | 22 (1) Benzodiazepine class: A fused 1,4-diazepine and | |
| 848 | + | 23 benzene ring structure with a phenyl connected to the | |
| 849 | + | 24 1,4-diazepine ring, with any substitution(s) or | |
| 850 | + | 25 replacement(s) on the 1,4-diazepine or benzene ring, any | |
| 851 | + | 26 substitution(s) on the phenyl ring, or any combination | |
| 852 | + | ||
| 853 | + | ||
| 854 | + | ||
| 855 | + | ||
| 856 | + | ||
| 857 | + | SB1987 Enrolled - 24 - LRB103 25792 RLC 57149 b | |
| 858 | + | ||
| 859 | + | ||
| 860 | + | SB1987 Enrolled- 25 -LRB103 25792 RLC 57149 b SB1987 Enrolled - 25 - LRB103 25792 RLC 57149 b | |
| 861 | + | SB1987 Enrolled - 25 - LRB103 25792 RLC 57149 b | |
| 862 | + | 1 thereof. Examples of this class include but are not | |
| 863 | + | 2 limited to: Clonazolam, Flualprazolam; or | |
| 864 | + | 3 (2) Thienodiazepine class: A fused 1,4-diazepine and | |
| 865 | + | 4 thiophene ring structure with a phenyl connected to the | |
| 866 | + | 5 1,4-diazepine ring, with any substitution(s) or | |
| 867 | + | 6 replacement(s) on the 1,4-diazepine or thiophene ring, any | |
| 868 | + | 7 substitution(s) on the phenyl ring, or any combination | |
| 869 | + | 8 thereof. Examples of this class include but are not | |
| 870 | + | 9 limited to: Etizolam. | |
| 871 | + | 10 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; | |
| 872 | + | 11 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. | |
| 873 | + | 12 8-14-18.) | |
| 874 | + | ||
| 875 | + | ||
| 876 | + | ||
| 877 | + | ||
| 878 | + | ||
| 879 | + | SB1987 Enrolled - 25 - LRB103 25792 RLC 57149 b |